Lytix Biopharma granted 3 MNOK from Oslo Regional Research Fund

15 Feb 2022 17:27 CET

Oslo, 15 February 2022. Lytix Biopharma – a clinical-stage company with an in
situ vaccination technology platform – has been awarded a NOK 3 million grant
from Oslo Regional Research Fund (Regionalt Forskningsfond Oslo) supporting the
development of the oncolytic molecule LTX-401 as treatment of patients with
hepatocellular carcinoma (HCC), a predominant form of liver cancer.

The goal of the preclinical development program is to assess the safety and
efficacy of LTX-401 and prepare for a clinical Phase I study. In preclinical
models, LTX-401 has demonstrated superior antitumor activity.

Liver cancer is estimated to be the third most common cause of cancer related
death globally. Hepatocellular carcinoma (HCC) accounts for 80-90 % of the cases
and is thus considered to be among the most severe cancer indications.

Øystein Rekdal, CEO of Lytix Biopharma says:
‘We are very pleased that Oslo Regional Research Fund shares our view of the
potential of LTX-401 and supports our efforts to improve the response rate in
cancer patients treated with immunotherapy.’


For more information, please contact:
Øystein Rekdal, CEO: +47 975 73 358
Gjest Breistein, CFO: +47 952 60 512

Lytix Biopharma in brief
Based in Oslo, Norway, Lytix Biopharma is a clinical stage biotech company
developing novel cancer immunotherapies, an area within cancer therapy that is
aimed at activating the patient’s immune system to fight cancer. The Company’s
technology is based on pioneering research in “host defense peptides” – nature’s
first line of defense towards foreign pathogens. Lytix Biopharma’s lead product,
LTX-315, is a first-in-class oncolytic molecule representing a new and superior
in situ therapeutic vaccination principle to boost anti-cancer immunity, with
the potential to be the ideal combination partner with other types of
immunotherapy. LTX-315 target cancer cells and disintegrate their cell
membranes, causing immunogenic cell death and release of a patient’s tumor
specific antigens. This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors such as
PBM Capital, a US based, healthcare-focused investment firm.

More information:
Access the news on Oslo Bors NewsWeb site